S. Bournazos

Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination

This study identifies non-neutralizing antibodies from vaccinated individuals that protect against SARS-CoV-2 in animal models, highlighting their role through Fc-mediated effector functions and conserved epitope binding.

Human FcγRIIIa activation on splenic macrophages drives the in vivo pathogenesis of dengue disease

This study shows that anti-DENV IgG antibodies drive dengue pathogenesis via FcγRIIIa on splenic macrophages, leading to inflammation and mortality.

Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo

This study evaluates the in vivo protective efficacy of SARS-CoV-2 monoclonal antibodies, finding that in vitro potency does not always predict in vivo activity and that effector function and combinations are critical for protection.

FcRn, but not FcgRs, drives maternal-fetal transplacental transport of human IgGantibodies

This study shows that FcRn, not FcγRs, is responsible for maternal-fetal transport of IgG antibodies, suggesting FcRn engineering could improve antibody transfer to the fetus.

A Combination of Two Human Monoclonal Antibodies Limits Fetal Damage by Zika Virus in Macaques

This study shows that two Fc-modified monoclonal antibodies limit fetal neurologic damage and vertical transmission of ZIKV in pregnant macaques.

Afucosylated maternal anti-dengue IgGs are a biomarker for susceptibility to dengue disease in their infants

The paper identifies afucosylation of maternal anti-dengue IgGs as a biomarker for infant susceptibility to symptomatic dengue infections and explains its mechanism involving Fc{gamma}RIIIa-mediated enhancement of viral replication.